[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644685":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":26,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":26,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":26,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Zhejiang Wenda Pharma Technology LTD.","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1:WD-890","EXPERIMENTAL","Drug:WD-890\n\nWD-890 tablet will be administered orally.",[13],"Drug: Drug:WD-890",{"label":15,"type":16,"description":17,"interventionNames":18},"Group 2: Placebo","PLACEBO_COMPARATOR","Drug: Placebo\n\nPlacebo tablet will be administered orally.",[19],"Drug: Drug: placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Drug:WD-890","WD-890 tablet will be administered orally.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Drug: placebo","Placebo tablet will be administered orally.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Lu Qianjin","CONTACT","+8613787097676","qianlu5860@gmail.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Hospital of Dermatology, Chinese Academy of Medical Sciences","RECRUITING","Nanjing","Jiangsu","210042","China","CN",{"type":47,"coordinates":48},"Point",[49,50],118.77778,32.06167,{"lat":50,"lon":49},[53],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"type":55,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100644685","phase-3-a-multicenter-randomized-double-blind-placebo-controlled-phase--study-to-evaluate-the-efficacy-and-safety-of-wd-890-tablets-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-100644685",false,"NCT07672561","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Male or female participant aged 18 to 75 years(inclusive)at the time of informed consent.\n* Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.\n* Body surface area (BSA) ≥10%, Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization\n\nExclusion Criteria:\n\n* Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, inverse, pustular,or drug induced psoriasis.)\n* Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted\n* Class III or IV congestive heart failure by New York Heart Association Criteria",true,"ALL","18 Years","75 Years",{"count":67,"type":68},375,"ESTIMATED","INTERVENTIONAL",[71],"PHASE3","The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.",[74],"Moderate to Severe Plaque Psoriasis","2026-06-26",{"date":77,"type":78},"2026-06-29","ACTUAL",{"date":80,"type":78},"2026-03-18",{"date":82,"type":68},"2027-07-30",{"name":5,"class":6},1]